Search
Search Results
-
RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse
Thyroid-associated ophthalmopathy (TAO) is the most common autoimmune inflammatory diseases of the orbit. The CD40-CD40L pathway has been regarded as...
-
Microcirculatory disturbance in acute liver injury is triggered by IFNγ-CD40 axis
BackgroundAcute liver failure (ALF) is a life-threatening disorder that progresses from self-limiting acute liver injury (ALI). Microcirculatory...
-
Clinical and Immunological Features, Genetic Variants, and Outcomes of Patients with CD40 Deficiency
PurposeInherited deficiencies of CD40 and CD40 ligand (CD40L) reflect the crucial immunological functions of CD40–CD40L interaction/signaling....
-
Spatial characterization and quantification of CD40 expression across cancer types
BackgroundCD40, a TNF receptor family member, is expressed by a variety of immune cells and is involved in the activation of both adaptive and innate...
-
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
CD40 signaling in classical type 1 dendritic cells (cDC1s) is required for CD8 T cell-mediated tumor rejection, but the underlying mechanisms are...
-
CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions
Exposure of lipopolysaccharide triggers macrophage pro-inflammatory polarization accompanied by metabolic reprogramming, characterized by elevated...
-
OX40 and CD40 Agonists for the Treatment of Lung Cancer
Lung cancer is the most common cause of morbidity and mortality in worldwide. Lung cancer is frequently discovered at advanced ages in a high number...
-
CD40 ligand stimulation affects the number and memory phenotypes of human peripheral CD8+ T cells
BackgroundCD40L is primarily expressed on activated CD4 + T cells and binds to CD40 which is expressed by various cells including dendritic cells,...
-
CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease with no approved disease-modifying therapies. Dazodalibep (DAZ), a novel...
-
Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study
BackgroundCervical cancer is the fourth most common cancer among women worldwide. Genome-wide association studies have revealed multiple susceptible...
-
X-linked hyper-immunoglobulin M syndrome harboring a novel CD40-ligand gene mutation: a case report
The X-linked hyper-IgM syndrome (X-HIGM1) is a rare primary immunodeficiency disorder (PID) caused by mutations in the gene encoding the CD154...
-
The Role of TNF-α, TNFRSF1A, and CD40 Gene Polymorphisms in Multiple Sclerosis in the Tomsk Region
Abstract —We studied the role of the rs1800629 polymorphism of the TNF- α gene; the rs4149584 polymorphism of the TNFRSF1A gene; and the rs6074022,...
-
CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
BackgroundColorectal cancer (CRC) with pulmonary metastasis usually indicates a poor prognosis, whereas patients may benefit from adoptive cell...
-
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
BackgroundStimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial...
-
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
HighlightsCD40 expression correlates with the type I anti-tumor response and better survival.
Pan-cancer bioinformatics characterization reveals...
-
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to...
-
CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics
CD40 ligand (CD40L) deficiency is a rare inborn error of immunity presenting with heterogeneous clinical manifestations. While a detailed...
-
Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
BackgroundAlthough chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy...
-
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
BackgroundWhile immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients...
